At a glance
ClinicalIndex Comparison RecordN/ACompleted· 331 enrolled
Drug / intervention
Insulin Pump (Medtronic Minimed Paradigm® VEO)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
OpT2mise Glucose Control in Type 2 DM With Insulin Pump Therapy
In Brief
A clinical study evaluating Insulin Pump (Medtronic Minimed Paradigm® VEO) for Diabetes Mellitus, Type 2. Completed, enrolled 331 participants across 36 sites in 13 countries.
Detailed Summary
The purpose of this study is to evaluate the comparative effectiveness of insulin pump therapy versus multiple daily injections in insulin-taking type 2 Diabetes Mellitus who are sub optimally controlled with multiple daily injections (MDI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesAustria, Canada, France, Germany, Hungary, Israel, Italy, Netherlands, North Macedonia, Serbia, South Africa, Spain, United States
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2010
Enrollment StartDec 2010
Primary CompletionFeb 2014
Study CompletionAug 2014
TodayJul 2026
First PostedAug 16, 2010
Enrollment StartDec 1, 2010
Primary CompletionFeb 1, 2014
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 15.9 years ago
Interventions
Insulin Pump (Medtronic Minimed Paradigm® VEO)device
The pump delivers insulin as specified by the patient